S'abonner

Dual loss of p110? PI3-kinase and SKAP (KNSTRN) expression leads to combined immunodeficiency and multisystem syndromic features - 04/08/18

Doi : 10.1016/j.jaci.2017.10.033 
Nigel Sharfe, PhD a, Ariana Karanxha, BSc a, Harjit Dadi, PhD a, Daniele Merico, PhD b, c, David Chitayat, MD d, Jo-Anne Herbrick, BSc b, Spencer Freeman, PhD e, Sergio Grinstein, PhD e, Chaim M. Roifman, MD a,
a Canadian Centre for Primary Immunodeficiency, Immunogenomic Laboratory, Division of Immunology & Allergy, Department of Pediatrics, Hospital for Sick Children, Toronto, Ontario, Canada 
b Centre for Applied Genomics, Hospital for Sick Children, Toronto, Ontario, Canada 
c Deep Genomics, Inc, Toronto, Ontario, Canada 
d Clinical and Metabolic Genetics, Hospital for Sick Children, Toronto, Ontario, Canada 
e The Program in Cell Biology, Hospital for Sick Children, Toronto, Ontario, Canada 

Corresponding author: Chaim M. Roifman, MD, Division of Immunology & Allergy, The Hospital for Sick Children, 555 University Ave, Toronto, Ontario, Canada M5G 1X8.Division of Immunology & AllergyThe Hospital for Sick Children555 University AveTorontoOntarioM5G 1X8Canada

Abstract

Background

We previously reported a novel syndrome characterized by combined immunodeficiency associated with severe developmental defects—subsequently known as Roifman-Chitayat syndrome (RCS; OMIM 613328). Linkage analysis identified 2 disease-associated loci.

Objectives

We sought to identify the genetic defect in these patients and characterize their immunologic cellular abnormalities.

Methods

Genetic, immunologic, protein, and cellular functional analyses were used to identify and characterize patient genetic deficiencies and aberrant patient cell behavior.

Results

Deleterious variants were found at both loci identified by linkage analysis: a homozygous stop codon in PI3-kinase p110δ (PIK3CD) and a homozygous frame shift mutation in SKAP (KNSTRN), both ablating protein expression. Patients with RCS display aberrant B-cell development, similar to p110δ-deficient mice, but also aberrant T-cell spreading, cell-cell interaction, and migration. Patients also display significant developmental abnormalities not seen in p110δ knockouts (eg, optic nerve atrophy and skeletal anomalies) that we ascribe to loss of SKAP. Aberrant SKAP expression can prolong anaphase and this may contribute to developmental defects. However, we also identified microtubule-associated protein 4 microtubule-binding protein as a novel SKAP-binding partner and show that it undergoes relocalization in patient T cells, with associated areas of aberrant microtubule hyperstabilization, likely contributing not only to the altered properties of RCS lymphoid cells but also to developmental defects.

Conclusions

The complex RCS presentation, with combined developmental and immunologic defects, is associated with a combined deficiency of 2 genes products, PI3-kinase p110δ and SKAP, both of which appear to play a significant role in the disease.

Le texte complet de cet article est disponible en PDF.

Key words : PIK3CD, PI3-kinase, SKAP, KNSTRN, syndromic, immunodeficiency, lymphocyte, MAP4, microtubule

Abbreviations used : CID, KO, MAP4, MTOC, NK, RCS, SKAP


Plan


 This work was supported by the Immunodeficiency Canada Distinguished Professorship in Immunology (CMR), the Program for Immunogenomics, and the Canadian Centre for Primary Immunodeficiency, the Jeffrey Modell Foundation, and Immunodeficiency Canada. The Centre for Applied Genomics at SickKids was supported by Genome Canada through the Ontario Genomics Institute, Canada Foundation for Innovation, and the Ontario Ministry of Research and Innovation.
 Disclosure of potential conflict of interest: D. Merico is an employee of Deep Genomics, Inc, and holds stock with Deep Genomics, Inc. S. Grinstein receives grant support from the Canadian Institutes of Health Research (CIHR). The rest of the authors declare that they have no relevant conflicts of interest.


© 2017  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 142 - N° 2

P. 618-629 - août 2018 Retour au numéro
Article précédent Article précédent
  • Mutations in PI3K110? cause impaired natural killer cell function partially rescued by rapamycin treatment
  • Raquel Ruiz-García, Alexander Vargas-Hernández, Ivan K. Chinn, Laura S. Angelo, Tram N. Cao, Zeynep Coban-Akdemir, Shalini N. Jhangiani, Qingchang Meng, Lisa R. Forbes, Donna M. Muzny, Luis M. Allende, Mohammed S. Ehlayel, Richard A. Gibbs, James R. Lupski, Gulbu Uzel, Jordan S. Orange, Emily M. Mace
| Article suivant Article suivant
  • Abnormal differentiation of B cells and megakaryocytes in patients with Roifman syndrome
  • Jessica Heremans, Josselyn E. Garcia-Perez, Ernest Turro, Susan M. Schlenner, Ingele Casteels, Roxanne Collin, Francis de Zegher, Daniel Greene, Stephanie Humblet-Baron, Sylvie Lesage, Patrick Matthys, Christopher J. Penkett, Karen Put, Kathleen Stirrups, National Institute for Health Research BioResource, Chantal Thys, Chris Van Geet, Erika Van Nieuwenhove, Carine Wouters, Isabelle Meyts, Kathleen Freson, Adrian Liston

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.